Literature DB >> 7817169

Lymph leakage after staging pelvic lymphadenectomy for prostatic carcinoma with and without heparin prophylaxis.

R Tomic1, T Granfors, J G Sjödin, L Ohberg.   

Abstract

The effect of heparin prophylaxis on lymph leakage and lymphocele formation was observed in a randomized, prospective, consecutive study of 48 patients undergoing lymph node dissection for staging carcinoma of the prostate. Subcutaneous low-dose heparin was given to 24 patients, and 24 without heparin prophylaxis constituted the control group. Lymph leakage per day was significantly greater and the leakage period longer in the heparin group than in the controls. The total of leaked lymph was notably greater and the incidence of lymphocele seven times higher in the heparin group than in the controls. All lymphoceles disappeared spontaneously in the first postoperative year. The results suggest high risk of prolonged lymph leakage and of lymphocele formation when low-dose heparin prophylaxis is given to patients undergoing a staging operation for prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7817169

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  3 in total

Review 1.  How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy.

Authors:  Hak J Lee; Christopher J Kane
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

2.  Occurrence of symptomatic lymphocele after open and robot-assisted radical prostatectomy.

Authors:  Giuseppe Magistro; Doan Tuong-Linh Le; Thilo Westhofen; Alexander Buchner; Boris Schlenker; Armin Becker; Christian G Stief
Journal:  Cent European J Urol       Date:  2021-09-09

3.  Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers.

Authors:  Aaron M Potretzke; Kelvin S Wong; Fangfang Shi; William Christensen; Tracy M Downs; E Jason Abel
Journal:  Urol Ann       Date:  2015 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.